Hua Medicine has announced that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).
The Infection Innovation Consortium: iiCON is managing a new £3.2 million Medical Research Council funded trial to enable progress into development of a new vaccine against pneumococcal disease.
The company's pci | bridgeTM enhances supply chain visibility and reduces time spent on manual activities such as forecasting, inventory management, reporting, supplier management and document sharing.
Takeda announced positive interim results from a Phase 3-enabling proof-of-concept study for mezagitamab (TAK-079), an anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN).
BirchBioMed announced the authorisation from Health Canada to conduct its Phase II/III randomised clinical trial of a naturally based compound, FS2, at multiple centres of expertise throughout Canada.
Patients receiving treatment for bowel cancer at Sheffield Teaching Hospitals NHS Foundation Trust will have the chance to try personalised 'vaccines' thanks to the launch of a NHS “matchmaking” service.
Shionogi & Co., Ltd. shared new data at IDWeek 2024 from the PROVE study, the largest global real-world evidence review of Fetroja/Fetcroja (cefiderocol).
The results showed that Ellorarxine significantly increases MAP2 expression at remarkably low concentrations (10nM), induces neurite outgrowth, increases mitochondrial viability to combat oxidative stress, ameliorates neuroinflammation and modifies G
